Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 19 - Any |
| Updated: | 1/17/2019 |
| Start Date: | February 1, 2016 |
| End Date: | February 2021 |
| Contact: | Christos Vaklavas, M.D. |
| Email: | cvaklavas@uabmc.edu |
| Phone: | 205-934-5677 |
A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer
This study will test how well a new combination of three drugs (Letrozole, Everolimus, and
TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to
definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers
while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational
drug that blocks the formation and growth of blood vessels that feed the cancer and promote
its growth. The goal of this study is to investigate the safety and efficacy of this
multitargeted approach in breast cancer.
TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to
definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers
while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational
drug that blocks the formation and growth of blood vessels that feed the cancer and promote
its growth. The goal of this study is to investigate the safety and efficacy of this
multitargeted approach in breast cancer.
In postmenopausal women with hormone receptor-positive and Her2 negative non-metastatic
breast cancer, downstaging or the achievement of a complete pathologic remission before
definitive surgery has been associated with the lowest risk of recurrence of breast cancer.
In order to achieve a better response in these patients in the preoperative setting, this
study combines 3 potentially synergistic agents. Letrozole blocks the synthesis of estrogens
and, in doing so, deprives the tumor from hormones which drive its growth. Everolimus is a
drug that blocks growth factor signaling which is essential for tumor cells to maintain their
growth and proliferation. Everolimus has already been shown to work very well in this subtype
of breast cancer in the recurrent and metastatic setting. TRC105 is an investigational agent
that prevents the formation and growth of new blood vessels that support tumors by providing
oxygen and nutrients.
The study has 2 components. First the investigators will determine the ideal in terms of
tolerance combination of doses of the 3 agents. Once the ideal regimen is determined, more
patients will be treated with the investigational combination. During this second stage, the
investigators will get a preliminary idea of how effective the investigational therapy is.
Further studies will need to be done to confirm the efficacy of the investigational
combination.
breast cancer, downstaging or the achievement of a complete pathologic remission before
definitive surgery has been associated with the lowest risk of recurrence of breast cancer.
In order to achieve a better response in these patients in the preoperative setting, this
study combines 3 potentially synergistic agents. Letrozole blocks the synthesis of estrogens
and, in doing so, deprives the tumor from hormones which drive its growth. Everolimus is a
drug that blocks growth factor signaling which is essential for tumor cells to maintain their
growth and proliferation. Everolimus has already been shown to work very well in this subtype
of breast cancer in the recurrent and metastatic setting. TRC105 is an investigational agent
that prevents the formation and growth of new blood vessels that support tumors by providing
oxygen and nutrients.
The study has 2 components. First the investigators will determine the ideal in terms of
tolerance combination of doses of the 3 agents. Once the ideal regimen is determined, more
patients will be treated with the investigational combination. During this second stage, the
investigators will get a preliminary idea of how effective the investigational therapy is.
Further studies will need to be done to confirm the efficacy of the investigational
combination.
Inclusion Criteria:
- Recent diagnosis of hormone receptor positive and HER2 negative breast cancer.
- Stage 2 and 3 hormone receptor positive and HER2 negative breast cancer (stage T2-4
but not inflammatory, N0-2, M0).
- Histological grade I, II or III according to the modified Bloom Richardson scale.
- No prior treatment specific for breast cancer.
- Postmenopausal status as defined by the National Comprehensive Cancer Network.
- ECOG performance status < 2 (Karnofsky > 60%).
- Must have signed study-specific informed consent.
- Liver Function Tests < 2.5 times the upper normal limit (UNL).
- ANC ≥ 1,500/mm3, platelets ≥ 100,000/mm3, Hemoglobin ≥ 10g%.
- Renal function: serum creatinine < 1.5 institutional UNL or creatinine clearance > 40
cc/min.
Exclusion Criteria:
- Inflammatory breast cancer.
- Pre- and peri-menopausal state.
- Pregnancy.
- Metastatic disease.
- HER2 positive breast cancer by immunohistochemistry or FISH.
- Triple negative breast cancer (hormone receptor and Her2 negative).
- Disease that cannot be followed by imaging studies.
We found this trial at
1
site
1720 2nd Ave S
Birmingham, Alabama 35233
Birmingham, Alabama 35233
(205) 934-4011
Principal Investigator: Christos Vaklavas, M.D.
Phone: 205-934-5677
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Click here to add this to my saved trials
